Product information and disease descriptionPlace of product in therapyApproaches to treatment
Current treatment options and standard of care
41 evidence topics · 9 sources
Anaphylm (dibutepinephrine)
Type I allergic reactions including anaphylaxis
- Manufacturer
- Aquestive Therapeutics
- Regulatory submission
- NDA resubmitted September 2026
- Launch
- Not announced
- Last updated